Are the high-costs of MS disease-modifying therapies justified?

Gavin Giovannoni, Chris Hawkes, Michael Levy, Emmanuelle Waubant

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)A3-A5
JournalMultiple Sclerosis and Related Disorders
Volume20
DOIs
StatePublished - Feb 1 2018

Fingerprint

Cost of Illness
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Are the high-costs of MS disease-modifying therapies justified? / Giovannoni, Gavin; Hawkes, Chris; Levy, Michael; Waubant, Emmanuelle.

In: Multiple Sclerosis and Related Disorders, Vol. 20, 01.02.2018, p. A3-A5.

Research output: Contribution to journalEditorial

Giovannoni, Gavin ; Hawkes, Chris ; Levy, Michael ; Waubant, Emmanuelle. / Are the high-costs of MS disease-modifying therapies justified?. In: Multiple Sclerosis and Related Disorders. 2018 ; Vol. 20. pp. A3-A5.
@article{30a850c4536f4d468b52461dca673349,
title = "Are the high-costs of MS disease-modifying therapies justified?",
author = "Gavin Giovannoni and Chris Hawkes and Michael Levy and Emmanuelle Waubant",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.msard.2018.02.018",
language = "English (US)",
volume = "20",
pages = "A3--A5",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Are the high-costs of MS disease-modifying therapies justified?

AU - Giovannoni, Gavin

AU - Hawkes, Chris

AU - Levy, Michael

AU - Waubant, Emmanuelle

PY - 2018/2/1

Y1 - 2018/2/1

UR - http://www.scopus.com/inward/record.url?scp=85044156491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044156491&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2018.02.018

DO - 10.1016/j.msard.2018.02.018

M3 - Editorial

C2 - 29579631

AN - SCOPUS:85044156491

VL - 20

SP - A3-A5

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -